title: Oseltamivir for the treatment of H1N1 influenza during pregnancy.
abstract: Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any trimester of pregnancy and postpartum. Oseltamivir (Tamiflu) is currently the recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. Oseltamivir has been demonstrated to prevent disease after exposure, treat infected individuals, as well as lessen the likelihood of complications. The physiologic adaptations of pregnancy alter the pharmacokinetics of this important drug. Evidence of these alterations, knowledge gaps, and future investigative directions to fill these knowledge gaps are highlighted.
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.|Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: R H
authors.initials: RH
authors.lastname: Beigi
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: V C
authors.initials: VC
authors.lastname: Pillai
authors.affiliation: Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.|Department of Pharmaceutical Sciences, School of Pharmacy, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.|Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: R
authors.initials: R
authors.lastname: Venkataramanan
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.|Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: S N
authors.initials: SN
authors.lastname: Caritis
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000201:enzymology / Q000472:pathogenicity; D007251:Influenza, Human / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053139:Oseltamivir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D053139:Oseltamivir; D009439:Neuraminidase